Form 8-K

8-K — MAIA Biotechnology, Inc.

Accession: 0001493152-26-045865

Filed: 2026-10-06

Period: 2026-10-06

CIK: 0001878313

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

EX-99.2 (ex99-2.htm)

GRAPHIC (ex99-1_001.jpg)

GRAPHIC (ex99-1_002.jpg)

GRAPHIC (ex99-1_003.jpg)

GRAPHIC (ex99-1_004.jpg)

GRAPHIC (ex99-1_005.jpg)

GRAPHIC (ex99-1_006.jpg)

GRAPHIC (ex99-1_007.jpg)

GRAPHIC (ex99-1_008.jpg)

GRAPHIC (ex99-1_009.jpg)

GRAPHIC (ex99-1_010.jpg)

GRAPHIC (ex99-1_011.jpg)

GRAPHIC (ex99-1_012.jpg)

GRAPHIC (ex99-1_013.jpg)

GRAPHIC (ex99-1_014.jpg)

GRAPHIC (ex99-1_015.jpg)

GRAPHIC (ex99-1_016.jpg)

GRAPHIC (ex99-1_017.jpg)

GRAPHIC (ex99-1_018.jpg)

GRAPHIC (ex99-1_019.jpg)

GRAPHIC (ex99-1_020.jpg)

GRAPHIC (ex99-1_021.jpg)

GRAPHIC (ex99-1_022.jpg)

GRAPHIC (ex99-1_023.jpg)

GRAPHIC (ex99-1_024.jpg)

GRAPHIC (ex99-1_025.jpg)

GRAPHIC (ex99-1_026.jpg)

GRAPHIC (ex99-1_027.jpg)

GRAPHIC (ex99-1_028.jpg)

GRAPHIC (ex99-2_001.jpg)

GRAPHIC (ex99-2_002.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001878313

2026-10-06

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

Current

Report

Pursuant

to Section 13 or 15(d)

The Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): October 6, 2026

MAIA

Biotechnology, Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-41455

83-1495913

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

444

West Lake Street, Suite

1700

Chicago,

60606

(Address

of principal executive offices)

(Zip

Code)

(312)

416-8592

(Registrant’s

telephone number, including area code)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock

MAIA

NYSE

American

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)

or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

7.01 Regulation FD Disclosure.

MAIA Biotechnology, Inc. (the “Company”) has prepared a presentation (the “Presentation”) that management intends

to use from time to time in presentations about the Company’s operations and performance on or after October 6, 2026, which Presentation

was posted to the Company’s website on October 6, 2026. The Presentation is furnished as Exhibit 99.1 to this Current Report on

Form 8-K.

The Company has prepared a summary (“Summary”) highlighting certain aspects of the operations and performance that management

intends to use in presentations on or after October 6, 2026, which Summary was posted to the Company’s website on October

6, 2026. The Summary is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The

information contained in each of the Presentation and the Summary is summary information that should be considered in the context of

the Company’s filings with the Securities and Exchange Commission and other public announcements the Company may make by press

release or otherwise from time to time. Each of the Presentation and the Summary speaks as of the date of this Report. While the Company

may elect to update the Presentation and/or the Summary in the future to reflect events and circumstances occurring or existing after

the date of this Report, the Company specifically disclaims any obligation to do so.

Each

of the Presentation and the Summary contains forward-looking statements, and as a result, investors should not place undue reliance on

these forward-looking statements.

The

information set forth in this Report, including, without limitation, the Presentation and the Summary, is not be deemed to be “filed”

for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject

to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended,

or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific

reference in such a filing. This Report (including the exhibits hereto) will not be deemed an admission as to the materiality of any

information required to be disclosed solely to satisfy the requirements of Regulation FD.

Forward-looking

Statements

The

Company cautions that all statements, other than statements of historical facts, contained in this Current Report on Form 8-K, or furnished

herewith, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other

factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different

from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,”

“could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,”

“project,” “intend,” “future,” “potential,” or “continue,” and other similar

expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are

not forward-looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that,

although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as

to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However,

these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control

that may cause actual results to differ materially from those expressed in any forward-looking statement, including, but not limited

to: (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs,

(ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory

filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing

process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for

our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain

intellectual property protection for our product candidates. Any forward-looking statement speaks only as of the date on which it was

made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information,

future events or otherwise, except as required by law.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

No.

Description

99.1

Presentation

99.2

Summary

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Dated:

October 6, 2026

MAIA

BIOTECHNOLOGY, INC.

By:

/s/

Vlad Vitoc

Name:

Vlad

Vitoc

Title:

Chief

Executive Officer

-3-

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit 99.1

EX-99.2

Filename: ex99-2.htm · Sequence: 3

Exhibit 99.2

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 4

Binary file (471406 bytes)

Download ex99-1_001.jpg

GRAPHIC

Filename: ex99-1_002.jpg · Sequence: 5

Binary file (962537 bytes)

Download ex99-1_002.jpg

GRAPHIC

Filename: ex99-1_003.jpg · Sequence: 6

Binary file (706188 bytes)

Download ex99-1_003.jpg

GRAPHIC

Filename: ex99-1_004.jpg · Sequence: 7

Binary file (617737 bytes)

Download ex99-1_004.jpg

GRAPHIC

Filename: ex99-1_005.jpg · Sequence: 8

Binary file (620447 bytes)

Download ex99-1_005.jpg

GRAPHIC

Filename: ex99-1_006.jpg · Sequence: 9

Binary file (637879 bytes)

Download ex99-1_006.jpg

GRAPHIC

Filename: ex99-1_007.jpg · Sequence: 10

Binary file (619149 bytes)

Download ex99-1_007.jpg

GRAPHIC

Filename: ex99-1_008.jpg · Sequence: 11

Binary file (540763 bytes)

Download ex99-1_008.jpg

GRAPHIC

Filename: ex99-1_009.jpg · Sequence: 12

Binary file (377748 bytes)

Download ex99-1_009.jpg

GRAPHIC

Filename: ex99-1_010.jpg · Sequence: 13

Binary file (574523 bytes)

Download ex99-1_010.jpg

GRAPHIC

Filename: ex99-1_011.jpg · Sequence: 14

Binary file (568855 bytes)

Download ex99-1_011.jpg

GRAPHIC

Filename: ex99-1_012.jpg · Sequence: 15

Binary file (521835 bytes)

Download ex99-1_012.jpg

GRAPHIC

Filename: ex99-1_013.jpg · Sequence: 16

Binary file (573465 bytes)

Download ex99-1_013.jpg

GRAPHIC

Filename: ex99-1_014.jpg · Sequence: 17

Binary file (446685 bytes)

Download ex99-1_014.jpg

GRAPHIC

Filename: ex99-1_015.jpg · Sequence: 18

Binary file (403855 bytes)

Download ex99-1_015.jpg

GRAPHIC

Filename: ex99-1_016.jpg · Sequence: 19

Binary file (545928 bytes)

Download ex99-1_016.jpg

GRAPHIC

Filename: ex99-1_017.jpg · Sequence: 20

Binary file (494088 bytes)

Download ex99-1_017.jpg

GRAPHIC

Filename: ex99-1_018.jpg · Sequence: 21

Binary file (529672 bytes)

Download ex99-1_018.jpg

GRAPHIC

Filename: ex99-1_019.jpg · Sequence: 22

Binary file (424749 bytes)

Download ex99-1_019.jpg

GRAPHIC

Filename: ex99-1_020.jpg · Sequence: 23

Binary file (634383 bytes)

Download ex99-1_020.jpg

GRAPHIC

Filename: ex99-1_021.jpg · Sequence: 24

Binary file (386161 bytes)

Download ex99-1_021.jpg

GRAPHIC

Filename: ex99-1_022.jpg · Sequence: 25

Binary file (680083 bytes)

Download ex99-1_022.jpg

GRAPHIC

Filename: ex99-1_023.jpg · Sequence: 26

Binary file (638142 bytes)

Download ex99-1_023.jpg

GRAPHIC

Filename: ex99-1_024.jpg · Sequence: 27

Binary file (607862 bytes)

Download ex99-1_024.jpg

GRAPHIC

Filename: ex99-1_025.jpg · Sequence: 28

Binary file (502249 bytes)

Download ex99-1_025.jpg

GRAPHIC

Filename: ex99-1_026.jpg · Sequence: 29

Binary file (364535 bytes)

Download ex99-1_026.jpg

GRAPHIC

Filename: ex99-1_027.jpg · Sequence: 30

Binary file (465499 bytes)

Download ex99-1_027.jpg

GRAPHIC

Filename: ex99-1_028.jpg · Sequence: 31

Binary file (522831 bytes)

Download ex99-1_028.jpg

GRAPHIC

Filename: ex99-2_001.jpg · Sequence: 32

Binary file (891061 bytes)

Download ex99-2_001.jpg

GRAPHIC

Filename: ex99-2_002.jpg · Sequence: 33

Binary file (786635 bytes)

Download ex99-2_002.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 49

v3.26.3

Cover

Oct. 06, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 06, 2026

Entity File Number

001-41455

Entity Registrant Name

MAIA

Biotechnology, Inc

Entity Central Index Key

0001878313

Entity Tax Identification Number

83-1495913

Entity Incorporation, State or Country Code

Entity Address, Address Line One

444

West Lake Street

Entity Address, Address Line Two

Suite

1700

Entity Address, City or Town

Chicago

Entity Address, State or Province

Entity Address, Postal Zip Code

60606

City Area Code

(312)

Local Phone Number

416-8592

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock

Trading Symbol

MAIA

Security Exchange Name

NYSEAMER

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration